Arcturus Therapeutics (NASDAQ:ARCT) Earns “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a report issued on Monday morning, Benzinga reports.

A number of other equities analysts have also commented on ARCT. Leerink Partnrs upgraded shares of Arcturus Therapeutics to a strong-buy rating in a research report on Monday, August 12th. HC Wainwright boosted their price target on shares of Arcturus Therapeutics from $60.00 to $63.00 and gave the company a buy rating in a research report on Thursday, August 8th. Leerink Partners assumed coverage on shares of Arcturus Therapeutics in a research report on Monday, August 12th. They issued an outperform rating and a $70.00 price target on the stock. Finally, William Blair restated an outperform rating on shares of Arcturus Therapeutics in a research report on Thursday, May 23rd. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus price target of $71.40.

Arcturus Therapeutics Stock Performance

Shares of NASDAQ ARCT opened at $20.98 on Monday. Arcturus Therapeutics has a 52-week low of $17.52 and a 52-week high of $45.00. The business has a fifty day moving average of $21.41 and a two-hundred day moving average of $28.12. The stock has a market cap of $565.03 million, a PE ratio of -5.37 and a beta of 2.60.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.85) by $1.21. The firm had revenue of $49.86 million during the quarter, compared to the consensus estimate of $21.00 million. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. During the same period last year, the firm posted ($1.98) EPS. Analysts predict that Arcturus Therapeutics will post -2.6 earnings per share for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of large investors have recently modified their holdings of ARCT. Millennium Management LLC lifted its position in shares of Arcturus Therapeutics by 250.1% during the second quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock worth $13,515,000 after purchasing an additional 396,505 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Arcturus Therapeutics by 22.4% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock valued at $38,061,000 after buying an additional 286,546 shares during the period. ARK Investment Management LLC lifted its holdings in Arcturus Therapeutics by 16.3% in the second quarter. ARK Investment Management LLC now owns 1,964,964 shares of the biotechnology company’s stock valued at $47,847,000 after buying an additional 275,315 shares during the period. Great Lakes Advisors LLC acquired a new position in Arcturus Therapeutics in the fourth quarter valued at approximately $6,531,000. Finally, Dimensional Fund Advisors LP lifted its holdings in Arcturus Therapeutics by 11.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,088,930 shares of the biotechnology company’s stock valued at $34,336,000 after buying an additional 115,087 shares during the period. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.